Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration

MLA

Se Woong Kang, et al. “Comparison of the Efficacy and Safety of SCD411 and Reference Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.” Scientific Reports, vol. 14, no. 1, June 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1038/s41598-024-65815-6.

APA

Se Woong Kang, Jaehwan Choi, Veeral S. Sheth, Agnieszka Nowosielska, Marta Misiuk-Hojlo, András Papp, David M. Brown, Jae-Ho Lee, & Yoreh Barak. (2024). Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Scientific Reports, 14(1), 1–9. https://doi.org/10.1038/s41598-024-65815-6

Chicago

Se Woong Kang, Jaehwan Choi, Veeral S. Sheth, Agnieszka Nowosielska, Marta Misiuk-Hojlo, András Papp, David M. Brown, Jae-Ho Lee, and Yoreh Barak. 2024. “Comparison of the Efficacy and Safety of SCD411 and Reference Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.” Scientific Reports 14 (1): 1–9. doi:10.1038/s41598-024-65815-6.